Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 11, 2014, Pages 1457-1489

  Italiano, Domenico ^a   Spina, Edoardo ^a   De Leon, Jose ^b,c  

^a UNIVERSITY OF MESSINA   (Italy)

^b Eastern State Hospital   (United States)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Antidepressants; Antiepileptics; Drug interactions; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CLOBAZAM; ESLICARBAZEPINE; FELBAMATE; FLUOXETINE; HARKOSERIDE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; REBOXETINE; RUFINAMIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VILAZODONE; ZONISAMIDE;

DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; PHARMACODYNAMICS; REVIEW; ANIMAL; DOSE RESPONSE; DRUG INTERACTION; ENZYME INDUCTION;

ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG SYNERGISM; ENZYME INDUCTION; HUMANS;

EID: 84911376283     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.956081     Document Type: Review

References (154)

1. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008;22:27-47
2. Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia 2012;53(Suppl 7):26-33
3. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007;369:1016-26
4. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblended randomised controlled trial. Lancet 2007;369:1000-15
5. Stahl SM. Antidepressants. In: Stahl SM, editor. Stahl's Essential Psychopharmacology. 4th edition. Cambridge University Press, New York; 2013. p. 284-369
6. Hermann B, Seidenberg M, Bell B. Psychiatric comorbidity in chronic epilepsy: identification, consequences, and treatment of major depression. Epilepsia 2000;41:S31-41
7. Prueter C, Norra C. Mood disorders and their treatment in patients with epilepsy. J Neuropsychiatry Clin Neurosci 2005;17:20-8
8. Mula M, Schmitz B, Sander WJ. The pharmacological treatment of depression in adults with epilepsy. Expert Opin Pharmacother 2008;9:3159-68
9. Mula M, Schmitz B. Depression in epilepsy: mechanisms and therapeutic approach. Ther Adv Neurol Disord 2009;2:337-44
10. Kanner AM. The treatment of depressive disorders in epilepsy: what all neurologists should know. Epilepsia 2013;54:3-12
11. Mehndiratta P, Sajatovic M. Treatments for patients with comorbid epilepsy and depression: a systematic literature review. Epilepsy Behav 2013;28:36-40
12. Harden CL, Goldstein MA. Mood disorders in patients with epilepsy: epidemiology and management. CNS Drugs 2002;16:291-302
13. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013;381:1672-82
14. Grunze HC. Anticonvulsants in bipolar disorder. J Ment Health 2010;19:127-41
15. Vieta E, Valentí M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs 2013;27:515-29
16. Mula M. Investigating psychotropic properties of antiepileptic drugs. Expert Rev Neurother 2013;13:639-46
17. Tan T, Barry P, Reken S, Baker M; Guideline Development Group. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ 2010;340:c1079
18. Dworkin RH, O'Connor AB, Audette J. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:S3-14
19. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev 2012;7:CD008943
20. Rickels K, Shiovitz TM, Ramey TS, et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol 2012;27:142-50
21. Vitali M, Tedeschini E, Mistretta M, et al. Adjunctive pregabalin in partial responders with major depressive disorder and residual anxiety. J Clin Psychopharmacol 2013;33:95-8
22. Casucci G, Villani V, Cologno D, D'Onofrio F. Polytherapy for migraine prophylaxis. Neurol Sci 2012;33:S147-50
23. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337-45
24. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2:347-56
25. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-81
26. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61:246-55
27. Johannesen Landmark C, Patsalos P. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 2010;10:119-40
28. de Leon J, Santoro V, D'Arrigo C, Spina E. Interactions between antiepileptics and second-generation antipsychotics. Exp Opin Drug Metab Toxicol 2012;8:311-34
29. Nemeroff CB, Preskorn S, Devane CL. Antidepressant drug-drug interactions: clinical relevance and risk management. CNS Spectr 2007;12:1-13
30. Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacology 2010;86:203-15
31. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008;30:1206-27
32. Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012;26:39-67
33. Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Exp Opin Drug Metab Toxicol 2014;10:712-46
34. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 2002;43(Suppl 2):37-44
35. Mula M. Anticonvulsants-antidepressants pharmacokinetic drug interactions: the role of the CYP450 system in psychopharmacology. Curr Drug Metab 2008;8:730-7
36. DeVane CL. Clinical significance of drug binding, protein binding, and binding displacement drug interactions. Psychopharmacol Bull 2002;36:5-21
37. Spina E. Drug interactions. In: Shorvon S, Perucca E, Engel J, editors. Treatment of Epilepsy. 3rd edition. Wiley-Blackwell Publishing Ltd, Oxford; 2009. p. 361-77
38. Cozza KL, Armstrong SC, Oesterheld JR. Concise guide to drug interaction principles for medical practice: cytochrome P450s, UGTs, P-Glycoproteins. 2nd edition. American Psychiatric Association, Washington, DC; 2003
39. Shin JG, Park JY, Kim MJ, et al. Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos 2002;30:1102-7
40. Lin JH. Transporter-mediated drug interactions. Clinical implications and in vitro assessment. Exp Opin Drug Metab Toxicol 2007;3:81-92
41. Zhang C, Kwan P, Zuo Z, Baum L. The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev 2012;64:930-42
42. O'Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol 2012;165:289-312
43. Akamine Y, Yasui-Furukori N, Ieiri I, Uno T. Psychotropic drug-drug interactions involving P-glycoprotein. CNS Drugs 2012;26:959-73
44. Brodie MJ, Mintzer S, Pack AM, et al. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia 2013;54:11-27
45. Vrzal R, Doricakova A, Novotna A, et al. Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: a possible cause of valproic acid-induced osteomalacia? Toxicol Lett 2011;200:146-53
46. Miziak B, Błaszczyk B, Chros̈cińska-Krawczyk M, et al. The problem of osteoporosis in epileptic patients taking antiepileptic drugs. Expert Opin Drug Saf 2014;13:935-46
47. de Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacol 2003;6:57-72
48. Benedetti MS, Whomsley R, Baltes E, Tonner F. Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction. Eur J Clin Pharmacol 2005;61:863-72
49. Sheth RD, Montouris G. Metabolic effects of AEDs: impact on body weight, lipids and glucose metabolism. Int Rev Neurobiol 2008;83:329-46
50. Isojärvi JI, Taubøll E, Herzog AG. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs 2005;19:207-23
51. Jakubus T, Michalska-Jakubus M, Lukawski K, et al. Atherosclerotic risk among children taking antiepileptic drugs. Pharmacol Rep 2009;61:411-23
52. Belcastro V, Striano P. Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy. Epilepsy Res 2012;102:1-7
53. Hill DS, Wlodarczyk BJ, Palacios AM, Finnell RH. Teratogenic effects of antiepileptic drugs. Expert Rev Neurother 2010;10:943-59
54. Labbate LA, Fava M, Rosenbaum JF, et al. Handbook of psychiatric drug therapy. Lippincott Williams & Wilkins, Philadelphia; 2010
55. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, et al. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998;38:112-21
56. Breyer-Pfaff U. The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man. Drug Metab Rev 2004;36:723-46
57. Spina E, Avenoso A, Campo GM, et al. Phenobarbital induces the 2- hydroxylation of desipramine. Ther Drug Monit 1996;18:60-4
58. Spina E, Avenoso A, Campo GM, et al. The effect of carbamazepine on the 2-hydroxylation of desipramine. Psychopharmacology (Berl) 1995;117:413-16
59. Szymura-Oleksiak J, Wyska E, Wasieczko A. Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. Psychopharmacology (Berl) 2001;154:38-42
60. Greb WH, Buscher G, Dierdorf HD, et al. The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine. Acta Psychiatry Scand Suppl 1989;350:95-8
61. Andersen BB, Mikkelsen M, Vesterager A, et al. No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res 1991;10:201-4
62. Kahn A, Shad MU, Preskhorn SH. Lack of sertraline efficacy probably due to an interaction with carbamazepine. J Clin Psychiatry 2000;61:526-7
63. Steinacher L, Vandel P, Zullino DF, et al. Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. Eur Neuropsychopharmacol 2002;12:255-60
64. Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 1996;11(Suppl 4):15-27
65. Sitsen J, Maris F, Timmer C. Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. Eur J Drug Metab Pharmacokinet 2001;26:109-21
66. Spaans E, van den Heuvel MW, Schnabel PG, et al. Concomitant use of mirtazapine and phenytoin: a drug-drug interactions study in healthy male subjects. Eur J Clin Pharmacol 2002;58:423-9
67. Ketter TA, Jenkins JB, Schroeder DH, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995;15:327-33
68. Helland A, Spigset O. Low serum concentrations of reboxetine in 2 patients treated with CYP3A4 inducers. J Clin Psychopharmacol 2007;27:308-10
69. Cerveny L, Svecova L, Anzenbacherova E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 2007;35:1032-41
70. de Leon J. False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part II: focus on bipolar disorder. J Clin Psychopharmacol 2014;34:291-6
71. Vandel S, Bertschy G, Jounet JM, et al. Valpromide increases the plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patients. Ther Drug Monit 1988;10:386-9
72. Bertschy G, Vandel S, Jounet JM, Allers G. Valpromide-amitriptyline interaction: increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide. Encephale 1990;16:43-5
73. Wong SL, Cavanaugh J, Shi H, et al. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther 1996;60:48-53
74. Fu C, Katzman M, Goldbloom DS. Valproate/nortriptyline interaction. J Clin Psychopharmacol 1994;14:205-6
75. Fehr C, Grunder G, Hiemke C, Dahmen N. Increase of serum clomipramine concentrations caused by valproate. J Clin Psychopharmacol 2000;20:493-4
76. Avoni P, Riva R, Albani F. Recurrence of absence seizures induced by a low dose of amitriptyline. Eur J Neurol 1996;3:272-4
77. DeToledo JC, Haddad H, Ramsay RE. Status epilepticus associated with the combination of valproic acid and clomipramine. Ther Drug Monit 1997;19:71-3
78. Roberts-Thomson KC, Teo KS, Young GD. Drug-induced Brugada syndrome with ST-T wave alternans and long QT. Intern Med J 2007;37:199-200
79. Unterecker S, Burger R, Hohage A, et al. Interaction of valproic acid and amitriptyline: analysis of therapeutic drug monitoring data under naturalistic conditions. J Clin Psychopharmacol 2013;33:561-4
80. Unterecker S, Reif A, Hempel S, et al. Interaction of valproic acid and the antidepressants doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions. Int Clin Psychopharmacol 2014;29:206-11
81. Kirchheiner J, Meineke I, Muller G, et al. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E-ad Z-doxepin in healthy volunteers. Pharmacogenetics 2002;12:571-80
82. Fogelman SM, Schmider J, Venkatakrishnan K, et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 1999;20:480-90
83. Baird P. The interactive metabolism effect of oxcarbazepine coadministered with tricyclic antidepressant therapy for OCD symptoms. J Clin Psychopharmacol 2003;23:419-20
84. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002;3:13-37
85. Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry 1992;55:412-13
86. Darley J. Interaction between phenytoin and fluoxetine. Seizure 1994;3:151-2
87. Woods DJ, Coulter DM, Pillans P. Interaction of phenytoin and fluoxetine. N Z Med J 1994;107:19
88. Shader RI, Greenblatt DJ, Von Moltke LL. Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 1994;14:375-6
89. Pearson HJ. Interaction of fluoxetine with carbamazepine. J Clin Psychiatry 1990;51:126
90. Grimsley SR, Jann MW, Carter JG, et al. Increased carbamazepine plasma concentrations after fluoxetine coadmnistration. Clin Pharmacol Ther 1991;50:10-15
91. Spina E, Avenoso A, Pollicino AM, et al. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993;15:247-50
92. Sovner R, Davis JM. A potential drug interaction between fluoxetine and valproic acid. J Clin Psychopharmacol 1991;11:389
93. Cruz-Flores S, Hayat GR, Mirza W. Valproic acid toxicity with fluoxetine therapy. Mo Med 1995;92:296-7
94. Lucena MI, Blanco E, Corrales MA, Berthier ML. Interaction of fluoxetine and valproic acid. Am J Psychiatry 1998;155:575
95. Reimers A, Skogvoll E, Sund JK, Spigset O. Drug interaction between lamotrigine and psychoactive drugs. J Clin Psychopharmacol 2005;25:342-8
96. Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991;84:583-4
97. Bonnet P, Vandel S, Nezelof S, et al. Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction? Therapie 1992;47:165
98. Mamiya K, Kojima K, Yukawa E, et al. Phenytoin intoxication induced by fluvoxamine. Ther Drug Monit 2001;23:75-7
99. Rapeport WG, Muirhead DC, Williams SA, et al. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry 1996;57(Suppl 1):24-8
100. Rapeport WG, Williams SA, Muirhead DC, et al. Absence of sertraline-mediated effect of the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 1996;57(Suppl 1):20-3
101. Berigan TR, Harazin J. A sertraline/valproic acid drug interaction. Int J Psychiatry Clin Pract 1999;3:287-8
102. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998;7:163-5
103. Christensen J, Sandgaard AP, Sidenius P, et al. Lack of interaction between sertraline and lamotrigine in psychiatric patients: a retrospective study. Pharmacopsychiatry 2012;45:119-21
104. Von Moltke LL, Greenblatt DJ, Grassi JM, et al. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry 1999;46:839-44
105. Von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001;29:1102-9
106. Moller SE, Larsen F, Khan AZ, Rolan PE. Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects. J Clin Psychopharmacol 2001;21:493-9
107. Popli AP, Tanquary J, Lamparella V, Masand PS. Bupropion and anticonvulsant drug interactions. Ann Clin Psychiatry 1995;7:99-101
108. Odishaw J, Chen C. Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy 2000;20:1448-53
109. Vigo DV, Baldessarini RJ. Anticonvulsants in the treatment of major depressive disorder: an overview. Harv Rev Psychiatry 2009;17:231-41
110. Malhi GS, Hitching R, Berk M, et al. Pharmacological management of unipolar depression. Acta Psychiatr Scand Suppl 2013;443:6-23
111. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, posttraumatic stress disorder and obsessivecompulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014;28:403-39
112. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009;122:S22-32
113. Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009;374:1252-61
114. Nishihara M, Arai YC, Yamamoto Y, et al. Combinations of low-dose antidepressants and low-dose pregabalin as useful adjuvants to opioids for intractable, painful bone metastases. Pain Physician 2013;16:E547-52
115. Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ 2010;182:E269-76
116. Shamliyan TA, Choi JY, Ramakrishnan R, et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med 2013;28:1225-37
117. Jackson JL, Shimeall W, Sessums L, et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ 2010;341:c5222
118. Krymchantowski AV, Jevoux C, Bigal ME. Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for non responders. J Headache Pain 2012;13:53-9
119. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011;2011:179674
120. Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010;28:5147-52
121. Bruno A, Micò U, Pandolfo G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 2012;26:1456-62
122. Vieta E, Günther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011;14:1029-49
123. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013;170:1249-62
124. Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010;121:404-14
125. Köhler S, Gaus S, Bschor T. The challenge of treatment in bipolar depression: evidence from clinical guidelines, treatment recommendations and complex treatment situations. Pharmacopsychiatry 2014;47:53-9
126. Köster M, Grohmann R, Engel RR, et al. Seizures during antidepressant treatment in psychiatric inpatients - results from the transnational pharmacovigilance project "Arzneimittelsicherheit in der Psychiatrie" (AMSP) 1993-2008. Psychopharmacology (Berl) 2013;230:191-201
127. Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007;62:345-54
128. Borowicz KK, Piskorska B, Ste¸pniak B, Czuczwar SJ. Effects of fluoxetine on the anticonvulsant action of valproate and ethosuximide in mouse model of myoclonic convulsions. Ann Agric Environ Med 2012;19:487-90
129. Foianini A, Joseph Wiegand T, Benowitz N. What is the role of lidocaine or phenytoin in tricyclic antidepressant-induced cardiotoxicity? Clin Toxicol (Phila) 2010;48:325-30
130. Schimpf R, Veltmann C, Papavassiliu T, et al. Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide. Heart Rhythm 2012;9:776-81
131. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71:1259-72
132. Nicholas LM, Ford AL, Esposito SM, et al. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 2003;64:883-9
133. Cramer JA. Tolerability of antiepileptic drugs: can we determine differences? Epilepsy Behav 2012;23:187-92
134. Zaccara G, Giovannelli F, Maratea D, et al. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Seizure 2013;22:528-36
135. Gartlehner G, Hansen RA, Thieda P, et al. Comparative Effectiveness of Second-generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Comparative Effectiveness. Review No. 7-EHC007-EF Agency for Healthcare Research and Quality, Rockville, MD; 2007. Available from: http://www.effectivehealthcare.ahrq.gov/repFiles/Antidepressants-Final-Report.pdf [Last accessed 25 June 2014]
136. Talley NJ. Functional nausea and vomiting. Aust Fam Physician 2007;36:694-7
137. Alam A, Voronovich Z, Carley JA. A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Prim Care Companion CNS Disord 2013;15(5
138. Brickel N, Gandhi P, VanLandingham K, et al. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K (v)7) potassium channels. Epilepsia 2012;53:606-12
139. Mago R, Mahajan R, Thase ME. Medically serious adverse effects of newer antidepressants. Curr Psychiatry Rep 2008;10:249-57
140. Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005;65:1976-8
141. Lange-Asschenfeldt C, Kojda G, Cordes J, et al. Epidemiology, symptoms, and treatment characteristics of hyponatremic psychiatric inpatients. J Clin Psychopharmacol 2013;33:799-805
142. Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm 2009;6:1335-41
143. Kogut C, Breden Crouse E, Vieweg V, et al. Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of cases reports. Ther Adv Drug Saf 2013;4:189-98
144. Johannesen L, Vicente J, Gray RA, et al. Improving the assessment of heart toxicity for all new drugs through translational regulatory science. Clin Pharmacol Ther 2014;15:501-8
145. Gahr M, Freudenmann RW, Connemann BJ, et al. Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions. Pharmacopsychiatry 2013;46:214-20
146. Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 2014;171:404-15
147. Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010;71:1565-75
148. Köse G, Arhan E, Unal B, et al. Valproate-associated coagulopathies in children during short-term treatment. J Child Neurol 2009;24:1493-8
149. Cheshire WP, Fealey RD. Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management. Drug Saf 2008;31:109-26
150. United States Food and Drug Administration. Antidepressant use in children, adolescents, and young adults. Revisions to product labeling. 2007. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM173233.pdf [Last accessed 25 June 2014]
151. US Department of Mental Health and Human Services. Statistical review and evaluation: antiepileptic drugs and suicidality. 2008. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf [Last accessed 25 June 2014]
152. Leon AC, Demirtas H, Li C, Hedeker D. Two propensity score-based strategies for a three-decade observational study: investigating psychotropic medications and suicide risk. Stat Med 2012;31:3255-60
153. Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. Bone 2012;51:606-13
154. Arrojo-Romero M, Tajes Alonso M, de Leon J. Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disorder. Case Rep Psychiatry 2013;2013:612459